Abstract
Glioblastoma multiforme (GBM) is one of the most malignant cancers in human brain. The prognosis of GBM is extremely poor because it is resistant to radiotherapy and chemotherapy. Improving understanding of the tumor biology brings some new hope to the treatment of GBM. In this review, we discuss the evidence that FoxM1 promotes the development and progression of GBM by regulating key factors involved in cell proliferation, epithelial to mesenchymal transition (EMT), invasion, angiogenesis and upregulating Wnt/β-catenin signalling. Our recent experimental findings are also summarized to prove that FoxM1 is a novel therapeutic target against GBM.
Keywords: Glioblastoma, tumorigenesis, EMT, invasion, angiogenesis, FoxM1, Wnt/β-catenin signaling.
Related Journals
Current Drug Safety
Current Medicinal Chemistry
Current Neuropharmacology
Current Pharmaceutical Analysis
Current Topics in Medicinal Chemistry
Current Vascular Pharmacology
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
CNS & Neurological Disorders - Drug Targets
Related Books
New Findings from Natural Substances
Mitochondrial DNA and the Immuno-inflammatory Response: New Frontiers to Control Specific Microbial Diseases
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Frontiers in Clinical Drug Research – Anti Allergy Agents
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Postbiotics: Science, Technology and Applications
Frontiers in Inflammation
59
1